REGULATORY
“Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
Japan should not simply apply price slashes for drugs that saw better-than-expected market expansions or changes in main indications but should fundamentally “re-do” their pricing based on new assumptions and their innovative value, Takanori Kawai, a lawmaker of the Democratic…
To read the full story
Related Article
REGULATORY
- LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





